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Abstract
Background: Type 2 diabetes (T2D) is strongly associated with cardiovascular risk and requires medications that
improve glycemic control and other cardiovascular risk factors. The authors aimed to assess the relative
effectiveness of pioglitazone (Pio), metformin (Met) and any sulfonylurea (SU) combinations in non-insulin-treated
T2D patients who were failing previous hypoglycemic therapy.
Methods: Over a 1-year period, two multicenter, open-labeled, controlled, 1-year, prospective, observational studies
evaluated patients with T2D (n = 4585) from routine clinical practice in Spain and Greece with the same protocol.
Patients were eligible if they had been prescribed Pio + SU, Pio + Met or SU + Met serving as a control cohort,
once they had failed with previous therapy. Anthropometric measurements, lipid and glycemic profiles, blood
pressure, and the proportions of patients at microvascular and macrovascular risk were assessed.
Results: All study treatment combinations rendered progressive 6-month and 12-month lipid, glycemic, and blood
pressure improvements. Pio combinations, especially Pio + Met, were associated with increases in HDL-cholesterol
and decreases in triglycerides and in the atherogenic index of plasma. The proportion of patients at high risk
decreased after 12 months in all study cohorts. Minor weight changes (gain or loss) and no treatment-related
fractures occurred during the study. The safety profile was good and proved similar among treatments, except for
more hypoglycemic episodes in patients receiving SU and for the occurrence of edema in patients using Pio
combinations. Serious cardiovascular events were rarely reported.
Conclusions: In patients with T2D failing prior hypoglycemic therapies, Pio combinations with SU or Met
(especially Pio + Met) improved blood lipid and glycemic profiles, decreasing the proportion of patients with a
high microvascular or macrovascular risk. The combination of Pio with SU or Met may therefore be recommended
for T2D second-line therapy in the routine clinical practice, particularly in patients with dyslipidemia.
Background
Type 2 diabetes mellitus (T2D) is a progressive and het-
erogeneous disease associated with macrovascular and
microvascular complications that increase morbidity and
mortality [1]. Cardiovascular disease (CVD) risk is
higher in patients with T2D than in the matched non-
diabetic population [2]. About half of deaths in patients
with T2D are caused by CVD, predominantly due to
ischemic heart disease [3]. Although controlling hyper-
glycemia is the primary goal for T2D treatments, appro-
priate T2D management requires addressing multiple
comorbidities. Effective interventions to revert dyslipide-
mia, hypercoagulation and hypertension, in addition to
hyperglycemia, have been shown to reduce diabetic
complications and mortality [4].
Pioglitazone (Pio) belongs to the group of thiazolidine-
diones (TZDs), agents that diminish insulin resistance
primarily by selective binding to peroxisome-prolifera-
tor-activated receptor-g (PPAR-g). TZDs have been
recommended as a second-line therapy in patients with
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monotherapy, particularly when they show multiple
metabolic derangements on top of hyperglycemia [4,5].
The PPAR-g receptor regulates expression of genes
involved in glucose, fatty acid, and cholesterol metabo-
lism, and plays a critical role in the vasculature [6]. It
has been suggested that Pio reduces hyperglycemia by
enhancing insulin sensitivity through PPAR-g binding,
but it also influences lipid metabolism and represses the
endothelial inflammatory gene expression involved in
atherosclerosis development by binding PPAR-a recep-
tors [7,8]. Nonetheless, there is a debate surrounding
the long-term risk/benefit ratio of TZDs, because TZDs’
pleiotropic effects, derived from the many actions of the
genes activated by PPAR-g agonism, may entail side
effects which would diminish or even counteract their
positive effects, resulting in a net increase in the risk of
macrovascular complications [9].
The high prevalence of diabetic dyslipidemia makes
many patients with T2D candidates for receiving sec-
ond-line combined treatment with Pio. However, few
randomized studies have compared the commonly pre-
scribed oral hypoglycemic combination of a sulfonylurea
(SU) plus metformin (Met) (SU + Met) with the Pio
combinations Pio + SU [10] or Pio + Met [11,12]. There
has only been one randomized study directly comparing
the aforementioned 3 combinations [13], and one obser-
vational study comparing Pio + Met versus SU + Met
[14], and neither evaluated lipid profile. A subanalysis of
the Prospective Pioglitazone Clinical Trial in Macrovas-
cular Events (PROactive) in patients with T2D and
e s t a b l i s h e dC V De v a l u a t e dt h el i p i dp r o f i l eo ft h e3
combinations, among others, but no comparisons were
performed among them; rather, Pio + SU and Pio + Met
were compared with the respective SU and Met mono-
therapies plus placebo, and SU + Met + Pio was com-
pared with SU + Met + placebo [15].
The present report corresponds to the data pooled
from two 1-year prospective, observational, controlled
cohort studies. Investigators evaluated the effectiveness
of Pio combinations, with SU or Met, compared to the
control combination of SU plus Met, in improving
metabolic derangements (including overweight/obesity,
dyslipidemia, hyperglycemia and arterial hypertension)
in a large sample of patients with T2D in routine clini-
cal practice in Spain and Greece.
Methods
Study design and patients
Two multicenter, controlled, 1-year, prospective, obser-
vational cohort studies were performed in Spain [16]
a n dG r e e c e[ 1 7 ]w i t ht h es a m ep r o t o c o l .T oo b t a i na
representative sample, physicians specializing in T2D
management from all regions of these countries were
invited to participate. Eligible patients had to be
18 years of age or older, of either gender, and had to
present a documented diagnosis of T2D that had been
inadequately controlled with their current hypoglycemic
therapy. These patients were newly prescribed with a
specific combined therapy (Pio + SU, Pio + Met, or SU
+ Met). The Pio doses required to participate had to be
15 or 30 mg/day. Patients with conditions or medica-
tions contraindicated with study drugs, or patients
requiring insulin therapy, were excluded.
Patients were included in the study if they were pre-
scribed 1 of the study therapies during routine clinical
visits. Cohort size was balanced by including blocks of 9
patients (3 per cohort), following the decision to pre-
scribe any of the 3 drug combinations. Investigators
were advised not to commence a new block unless the
previous one was completed.
The study protocol complied with the Declaration of
Helsinki and regulations for postauthorization observa-
tional studies in Spain and Greece, and was approved by
accredited Ethics Committees from both countries. All
patients signed and dated written Informed Consent
Forms, and data was collected in Case Report Forms
where anonymity was maintained.
Assessments and procedures
Procedure at baseline entailed the collection of sociode-
mographic, anthropometric, clinical, and laboratory data.
This included information about the age of T2D diagno-
sis and T2D duration, measurement of fasting plasma
glucose (FPG) and glycosylated hemoglobin (HbA1c),
serum high-density lipoprotein cholesterol (HDL-C),
total cholesterol (total-C), low-density lipoprotein cho-
lesterol (LDL-C) and triglycerides, systolic (SBP) and
diastolic (DBP) blood pressures, cardiovascular history
(arterial hypertension, microvascular and macrovascular
disorders, peripheral arterial occlusive disease), and
measurements of hepatic (alanine transaminase, ALT)
and renal (serum creatinine) functions.
Effectiveness was measured by changes in several bio-
chemical tests for blood obtained at 3 time points: dur-
ing the 30 days prior to starting the combined study
therapies (baseline assessment), and at the 6-month (±1)
and 12-month (±1) follow-up visits. Because only a few
studies in T2D patients have focused on patients’ lipid
profiles, and given the authors’ interest in macrovascular
risk, the HDL-C was considered the primary endpoint.
All the laboratory measurements were assessed after
an overnight fast. HDL-C, total-C, and triglycerides
were assayed by enzymatic methods, and LDL-C was
estimated using the Friedewald equation. FPG was mea-
sured by means of a glucose-oxidase-based method.
HbA1c was determined by a high-performance liquid
chromatographic method. Local clinical laboratories
Rodríguez et al. Cardiovascular Diabetology 2011, 10:18
http://www.cardiab.com/content/10/1/18
Page 2 of 14assayed all tests using their working standards. Raw
results were standardized against the reference ranges
from the laboratory that analyzed more samples. SBP
and DBP were measured by using a standard brachial
cuff technique after having the patient rest for 10 min-
utes in a seated position.
In addition, some estimations regarding cardiovascular
risk were performed for the 3 moments in which the
patients were assessed: 1) quotient total-C/HDL-C and
atherogenic index of plasma (AIP), calculated as log (tri-
glycerides/HDL-C) [18]; 2) categorization of patients
into cardiovascular risk ranges estimated by the Eur-
opean Diabetes Policy Group (EDPG), based on glyce-
m i ca n dl i p i dp r o f i l e s[ 1 9 ] ;a n d3 )a c h i e v e m e n to f
targets for diabetic patients related to lipid profile
according to both EDPG [19] and International Diabetes
Federation (IDF) recommendations [4].
Weight, measured to the nearest 0.1 kg, alanine trans-
aminase (ALT), and creatinine were also monitored
throughout the study. Safety was also supervised by
recording hypoglycemic episodes and adverse events
(AEs). AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA), version 3.3.
Statistical methods
Sample size was calculated at 2190 patients for each
country to provide a 90% power to detect a difference of
at least 0.05 mmol/l between 2 means of HDL-C using a
two-group t-test with a 0.05 two-sided significance level.
This sample size considered 3 cohorts of patients and
assumed a 40% withdrawal rate and a common standard
deviation of 0.24 mmol/l.
Analyses of effectiveness included data from patients
who started study treatments and had at least 1 postba-
seline assessment. Missing values were calculated using
the last observation carried forward (LOCF) method. As
a sensitivity analysis, efficacy was also evaluated in the
actual (observed) 12-month values.
Baseline variables were summarized by descriptive sta-
tistics, as were changes of the study variables (standar-
dized biochemical tests, blood pressure, weight, and
AIP) from baseline to the 6-month and 12-month visits.
Vascular and cardiovascular risks across cohorts were
evaluated by examining the proportion of patients in
each EDPG risk range (observed 12-month data) for gly-
cemic and blood lipid tests [19]. Compliance with low-
risk EDPG [19] and IDF [4] lipid profile goals was
expressed as a percentage difference of cohort means
above or below target levels. Frequencies of hypoglyce-
mic episodes and AEs were compared by chi-square or
Fisher exact tests.
The EDPG cardiovascular risk ranges were also used
to estimate the likelihood of being at low risk versus
higher risk levels by logistic regression analyses done
separately for each relevant glycemic and blood lipid
c o m p o n e n t( H b A 1 c ,F P G ,H D L - C ,t o t a l - C ,L D L - Ca n d
triglycerides). These models adjusted for the study treat-
ment, gender, age, baseline weight, duration of diabetes,
usage of lipid-lowering drugs (for blood lipid profile),
and baseline levels of each modeled component.
Results
Patients and treatments
Between May 2002 and November 2005 4585 patients
were evaluated. In total, 485 left the study prematurely.
The proportion of patients withdrawing prematurely
was slightly greater in the Pio cohorts. Withdrawal
causes were similar among cohorts, except when it
came to consent withdrawals, which were more frequent
with Pio. Figure 1 shows patients’ distribution through-
out the study.
Previous hypoglycemic agents were mainly SU (54%)
or Met (43%). Most patients maintained their prior
hypoglycemic drug with the new added agent. Pio was
g i v e na t3 0m gd a i l yd o s e se x c e p tf o r1 8 . 5 %o fp a t i e n t s
receiving 15 mg/day, with few changes by Month 12.
The most prescribed SUs were similarly distributed
among cohorts; glimepiride, gliclazide, and glibencla-
mide were the most common. The same median dose
for Met and the most prescribed SUs were maintained
in all cohorts (Met: 1700 mg/day; glimepiride: 4 mg/day;
gliclazide: 160 mg/day; and glibenclamide: 15 mg/day).
Some patients concomitantly received lipid-lowering
a g e n t s( 2 7 %P i o+S U ,2 8 %P i o+M e t ,2 9 %S U+M e t )
and/or antihypertensive therapy (44% Pio + SU, 40% Pio +
Met, 45% SU + Met) throughout the whole study.
Baseline assessments
Patients’ baseline characteristics are shown in Table 1.
Mean total-C and LDL-C were above the low EDPG
risk range and FPG and HbA1c above the nondiabetic
range. Physicians’ prescription criteria were guided by
the clinical status of individual patients, resulting in dif-
ferences between cohorts on some baseline variables.
Patients prescribed with Pio + Met had an overall worse
clinical status in terms of cardiovascular risk factors,
including a greater body mass index (BMI), than
patients of other cohorts. Patients treated with Pio + SU
had the lowest baseline weight, BMI, and proportion of
obesity, but the highest FPG and HbA1c. Patients
receiving SU + Met had the lowest baseline FPG and
HbA1c.
Evolution of blood lipids
Baseline to Month 12 changes in HDL-C (Figure 2A
and Table 2) showed a progressive increase that was
about two times greater with Pio combinations than
with SU + Met.
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gressively (Figures 2B to 2F and Table 2). Differences
among cohorts on LDL-C and total-C were less
important. Triglycerides also decreased more with Pio
combinations, especially Pio + Met. In all cohorts,
lipid profile changes were more pronounced among
patients who received concomitant lipid-lowering
medications than among those who did not (data not
shown).
Evolution of glycemic variables
The 12-month reductions in HbA1c (mean [SD] reduc-
tions: -1.3 [1.4] % Pio + SU, -1.3 [1.3] % Pio + Met, -0.9
[1.3] % SU + Met; Figure 3A), and FPG (-2.7 [0.1]
mmol/l in Pio cohorts vs -2.1 [0.1] mmol/l with SU +
Met; Figure 3B) were both greater with Pio combina-
tions than with SU + Met.
Evolution of blood pressure
There were slight reductions of both systolic (SBP) and
diastolic blood pressure (DBP) measurements, in all
cohorts (Figure 4).
Evolution of anthropometric variables
Mean weight and BMI values in Pio + Met were the
h i g h e s ta tb a s e l i n e( T a b l e1 )a n dt h r o u g h o u tt h ew h o l e
study (data not shown). There were only minor changes
after 12 months resulting in a mean weight gain with
Pio + SU (+ 0.8 kg), and a weight decrease with Pio +
Met (-0.7 kg) and SU + Met (-0.9 kg).
Figure 1 Distribution of patients throughout the study.
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Progressive 12-month reductions of AIP were greater
with Pio treatments (Figure 2F).
Considering EDPG risk ranges, the proportions of
patients at low risk increased in all cohorts after 12
months, in particular regarding total-C, triglycerides,
and glycosylated hemoglobin (Figure 5). In general, the
increases of patients at low risk were more noticeable
with Pio combinations.
Logistic regression analyses revealed a consistently
lower likelihood of being in high risk EDPG categories
for Pio cohorts for HDL-C (odds ratios versus the SU +
Met cohort: 0.671, 95% CI: 0.545 - 0.827 Pio + SU; 0.672,
0.539 - 0.837 Pio + Met), triglycerides (0.597, 0.500 -
0.713 Pio + SU; 0.559, 0.463 - 0.674 Pio + Met), HbA1c
(0.528, 0.440 - 0.633 Pio + SU; 0.595, 0.494 - 0.717 Pio +
Met), and FPG (0.771, 0.607 - 0.981 Pio + SU; 0.654,
0.514 - 0.830 Pio + Met). For total-C, lower likelihood
Table 1 Patients’ characteristics at baseline (N = 4585)
Pio + SU
n = 1709
Pio + Met
n = 1496
SU + Met
n = 1380
Sociodemographics
Age, years 62.5 ± 9.8 [3] 58.7 ± 10.5 [4] 62.2 ± 9.8 [5]
Gender, females 869 (50.8) [0] 795 (53.1) [0] 733 (53.1) [0]
Smoker, yes 333 (19.6) [7] 341 (22.9) [4] 273 (19.9) [8]
Anthropometrics
Height, cm 164 ± 9 [0] 165 ± 9 [1] 164 ± 9 [2]
Weight, kg 77 ± 13 [0] 85 ± 15 [1] 79 ± 14 [2]
BMI,
† kg/m
2 28.8 ± 4.5 [0] 31.2 ± 5.2 [1] 29.6 ± 4.6 [2]
Obese patients (BMI ≥30 kg/m
2) 532 (31.1) [0] 777 (52.0) [1] 537 (39.0) [2]
Glycemic profile
Age T2D diag.,* years 53.9 ± 10.4 [8] 51.7 ± 10.4 [15] 53.8 ± 10.2 [10]
T2D duration, years 8.6 ± 7.0 [10] 7.0 ± 6.3 [19] 8.4 ± 6.9 [11]
FPG, mmol/l 10.8 ± 2.5 [77] 10.4 ± 2.6 [55] 10.2 ± 2.5 [56]
HbA1c, % 8.4 ± 1.7 [59] 8.2 ± 1.6 [50] 8.0 ± 1.6 [43]
Lipid profile
HDL-C, mmol/l 1.18 ± 0.28 [114] 1.17 ± 0.30 [82] 1.19 ± 0.28 [95]
LDL-C, mmol/l 3.99 ± 0.69 [207] 3.94 ± 0.71 [218] 3.96 ± 0.69 [192]
Total-C, mmol/l 5.58 ± 1.12 [58] 5.59 ± 1.14 [56] 5.47 ± 1.14 [59]
Triglycerides, mmol/l 2.05 ± 0.83 [56] 2.15 ± 0.86 [63] 2.00 ± 0.81 [41]
AIP 0.59 ± 0.22 [160] 0.61 ± 0.21 [135] 0.57 ± 0.21 [134]
Cardiovascular status
SBP, mm Hg 142 ± 19 [8] 142 ± 18 [5] 143 ± 18 [3]
DBP, mm Hg 82 ± 10 [8] 84 ± 10 [5] 83 ± 10 [3]
Arterial hypertension 999 (58.5) [0] 867 (58.0) [0] 865 (62.7) [0]
Microvascular history 320 (19.1) [34] 265 (18.0) [27] 301 (22.3) [33]
Macrovascular history 328 (19.2) [0] 256 (17.1) [0] 303 (22.0) [0]
Angina pectoris 153 (9.0) [0] 128 (8.6) [0] 146 (10.6) [0]
Myocardial infarction 110 (6.6) [34] 58 (3.6) [33] 86 (6.4) [32]
Heart failure 49 (2.9) [0] 42 (2.8) [0] 68 (4.9) [1]
Ictus 63 (3.8) [31] 52 (3.6) [34] 64 (4.7) [30]
Perip. arterial occlusive disease 125 (7.5) [39] 119 (8.1) [33] 130 (9.6) [31]
Hepatic and renal function
ALT, IU/l 28.6 ± 11.5 74 29.4 ± 12.0 84 29.2 ± 11.8 71
Creatinine, μmol/l 90 ± 25 [44] 89 ± 23 [45] 90 ± 24 [55]
Values are either the numbers of patients with their percentages within parenthesis or means ± standard deviations. Values within brackets indicate the numbers
of patients with missing data for that variable.
*Age at diagnosis of T2D. † BMI classification according to the Spanish Society for the Study of Obesity (SEEDO) [55].
Values are either number of patients with their percentages within parentheses or mean ± standard deviation. Values within brackets indicate the number of
patients with missing data for that variable.
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Page 5 of 14Figure 2 Evolution of HDL-cholesterol (A), LDL-cholesterol (B), total-cholesterol (C), triglycerides (D), total-cholesterol/HDL-
cholesterol (E), and atherogenic index of plasma (F), from baseline to Month 12. Data points are mean values and error bars represent
95% CIs. The 2 dashed horizontal lines mark the range between mean levels of each variable for the total population at baseline and at Month
12 (LOCF data).
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(0.799, 0.654 - 0.974) and not significant with Pio + SU
(0.898, 0.742 - 1.086). Results related to LDL-C were not
significantly different among the study cohorts.
Compliance with EDPG and IDF lipid profile goals
improved from baseline (Figure 6). Mean HDL-C and tri-
glycerides reached the low risk range (as per EDPG) or
surpassed target levels (as per the IDF) after 12 months
of treatment. Mean LDL-C approached but did not reach
target levels.
Tolerability and safety
Table 3 summarizes the main safety data. Among
patients receiving SUs, there was a higher incidence of
patients recording at least one hypoglycemic episode.
Few hypoglycemic episodes were severe, these occurred
at similar frequencies among cohorts.
Few patients (284/4585, 6.2%) had at least 1 AE dur-
ing the study, evenly distributed among cohorts. The
incidence of related AEs was low, although higher in Pio
cohorts, with significant differences (p = 0.003) among
cohorts. The most common related AEs were gastroin-
testinal disorders, similarly distributed among cohorts;
and general disorders, with higher proportion in the Pio
cohorts, primarily edema. There were two incidental hip
fractures in the Pio + SU group that the investigators
considered as unrelated to study treatments.
Table 2 Changes in lipid measurements and atherogenic
index of plasma from baseline to Month 12
Pio + SU
n = 1709
Pio + Met
n = 1496
SU + Met
n = 1380
HDL-C [108] [96] [85]
Change in means, % 6 6 3
Change in medians, % 7 9 2
Mean change, mmol/l 0.07 0.08 0.03
LDL-C [128] [125] [127]
Change in means, % -8 -8 -7
Change in medians, % -5 -6 -5
Mean change, mmol/l -0.32 -0.32 -0.26
Total-C [70] [70] [72]
Change in means, % -9 -9 -7
Change in medians, % -7 -8 -5
Mean change, mmol/l -0.51 -0.54 -0.39
Triglycerides [53] [54] [39]
Change in means, % -17 -19 -10
Change in medians, % -15 -18 -9
Mean change, mmol/l -0.35 -0.41 -0.21
AIP [135] [124] [105]
Change in means, % -18 -18 -10
Change in medians, % -18 -18 -9
Mean change -0.11 -0.12 -0.06
Values within brackets indicate the number of patients with missing data for
that variable. The numbers represent the percentage changes in the mean
and median values, and the absolute mean change, from baseline to Month
12 (LOCF data).
Figure 3 Evolution of glycosylated hemoglobin (A) and fasting plasma glucose (B) from baseline to Month 12.D a t ap o i n t sa r em e a n
values and error bars represent 95% CIs. The 2 dashed horizontal lines mark the range between baseline and Month 12 (LOCF data) mean levels
of each variable for the total population.
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(0.8%), without differences among cohorts. Six patients
(0.1%), 2 per cohort, had an AE resulting in death, but
none were related to the study treatments in the physi-
cians’ criteria.
Sensitivity analyses
Twelve-month data showed greater benefits with Pio
combinations, especially with Pio + Met, than LOCF
data (Figures 2 to 4). The progressive 12-month
improvements were predictably blunted whenever some
Month 6 data were included in the LOCF analyses.
Discussion
In this prospective, observational, controlled cohort study
in patients with T2D who had failed to achieve therapeu-
tic goals in prior therapy, clinical and biochemical vari-
ables associated with cardiovascular risk progressively
improved after 12-month combined treatments. These
improvements were greater in patients treated with Pio
combinations, particularly Pio + Met, than with the con-
trol combination SU + Met. In line with the results from
prior randomized trials with Pio [10-12,15,20-23], such
benefits were especially noticeable for the rise in HDL-C
and the decline in triglycerides.
Decreased HDL-C, increased LDL-C and triglycerides,
hyperglycemia, hypertension, and smoking have classi-
cally been reported as independent risk factors for CVD
in patients with T2D [24]. The major cardiovascular and
diabetes organizations have established target levels to
be achieved by diabetic patients for LDL-C, HDL-C, and
triglycerides [4,19,25,26].
Although lowering LDL-C to target has been the main
goal to reduce the risk of CVD in the general population
[27], LDL-C particle size, in addition to total concentra-
tion, has been associated with the pathogenesis of ather-
osclerosis and cardiovascular risk [28]. Pio treatments
positively affect the T2D atherogenic profile by signifi-
cantly increasing the size of LDL and HDL particles
[29,30]. Thus an additional benefit of Pio could be
expected from its effects over LDL subfractions, which
are not visible by total LDL-C measurements. In con-
trast, a considerable residual cardiovascular risk still
remains, largely attributed to low HDL-C and high tri-
glycerides in diabetic patients [27,31], and concerns
have been expressed regarding the ability of statins to
correct the atherogenic dyslipidemia of patients with
T2D, which is characterized by low HDL-C levels, ele-
vated triglycerides, and predominance of small, dense
LDL particles [32]. The AIP is a surrogate marker of
atherosclerosis inversely correlated with LDL particle
size [18,33]. In the present study, as in prior research
[34-36], reductions of AIP were observed in the cohorts
treated with Pio combinations. Moreover, because AIP
is inversely correlated with insulin sensitivity [36], this
data together suggests that the insulin-sensitizing role of
Figure 4 Evolution of systolic (SBP, panel A) and diastolic (DBP, panel B) blood pressures from baseline to Month 12. Data points are
mean values and error bars represent 95% CIs. The two dashed horizontal lines mark the range between mean levels of each variable for the
total population at baseline and at Month 12 (LOCF data).
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atherogenic dyslipidemia. Recent reports have further
reinforced the role of Pio to reduce the risk of CVD
through its effects on other surrogate markers, such as
the carotid intima-media thickness [37] and the ather-
oma plaque size [38]. Therefore, current evidence sup-
ports that improvements in dyslipidemia (increasing
HDL-C and reducing triglycerides and AIP), as observed
in the present study, might render significant antiathero-
genic effects, potentially diminishing the risk for macro-
vascular complications.
Although the evidence just mentioned suggests that
the pleiotropic effects of Pio provide a benefit over a
range of metabolic disturbances in patients with T2D,
Figure 5 Proportion of patients distributed according to the risk ranges for cardiovascular events and vascular complications
estimated by the EDPG, related to lipid profile (A-D) and glycemic status (E-F).
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Page 9 of 14Figure 6 Percentage deviations of mean values of lipid profile from the recommended targets for diabetic patients according to the
criteria for low-risk EDPG range (panels A, C, E) [19] and IDF lipid targets (panels B, D, F) [4]. Panels A-B: HDL-C, C-D: LDL-C, and E-F:
triglycerides. Level zero marks the cutpoint for each component, values over zero indicate percentage differences over unfulfilled target levels,
and values below zero are the percentage differences over fulfilled target levels. HDL-C values have been reversed accordingly. Framed numbers
indicate percentage changes from baseline to Month 12 within each cohort.
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macrovascular complications beyond improvement of
glycemic and lipid profiles remains yet to be proven.
This would require the investigation of clinical end-
points in long-term prospective studies that are not yet
available [39]. While the results of the PROactive trial
pointed in that direction in patients with established
CVD [40-42], there is no evidence published in this
regard among the general population of patients with
T2D [43-46]. The results from the present study are of
particular interest for the Pio + Met combination as
they suggest that additive or, speculatively, synergistic
nonhypoglycemic effects may occur to improve meta-
bolic disturbances related to cardiovascular risk in
patients with T2D. Metformin has been shown to have
relevant positive effects on hard clinical endpoints
[47,48] and, despite the reports of an enhanced risk of
heart failure associated to TZD use [49], Pio has been
associated with reducing the risk of nonfatal myocardial
infarction, death, and stroke [40,50]. Additionally, sev-
eral meta-analyses failed to show an association between
Pio and increased cardiovascular risk [50,51], and the
fluid retention related to TZD treatment has not been
associated with an increased risk of cardiovascular death
similar to that associated with congestive heart failure
secondary to left ventricular dysfunction [46]. Further-
more, echocardiography evaluations during Pio treat-
ment have reported small and inconsistent effects
[52,53], supporting the notion that TZD do not have a
direct impact on heart muscle [54]. Notwithstanding,
caution should be exerted in susceptible patients, and
the assessment of specific diagnostic markers readily
available in the routine practice, such as the assay of
natriuretic peptide levels [52], may be of help before
starting TZD therapy in patients without manifest car-
diac disease. In this study, the Pio + Met combination
was started mostly by patients who were previously on
Met monotherapy, and these were generally overweight
or obese. Switching from SU monotherapy to the Pio +
Met combination might represent an advantage to some
patients who are routinely switched to SU + Met when
they start combined therapy after failing to achieve
Table 3 Summary of the main safety data during the study
Pio + SU
n = 1709
Pio + Met
n = 1496
SU + Met
n = 1380
Hypoglycemic episodes
At least one 175 (10.3) [2] 91 (6.1) [6] 134 (9.7) [1]
Severe 5 (0.3) [36] 4 (0.3) [36] 5 (0.4) [26]
Adverse events [0] [0] [0]
At least one adverse event 113 (6.6) 98 (6.6) 73 (5.3)
Related to study treatments* 70 (4.1) 60 (4.0) 28 (2.0)
Gastrointestinal disorders 13 (0.8) 15 (1.0) 15 (1.1)
General disorders 28 (1.6) 25 (1.7) 3 (0.2)
Edema 26 (1.5) 22 (1.5) 2 (0.1)
At least one serious adverse event 13 (0.8) 10 (0.7) 12 (0.9)
Description of all serious AEs (by body system):
Cardiac disorders 4 (0.2) 2 (0.1) 2 (0.1)
Gastrointestinal disorders - - 1 (0.1)
General disorders - - 1 (0.1)
Infections and infestations - 2 (0.1) -
Injury, poisoning, and procedural complications 1 (0.1) - -
Metabolism and nutrition disorders 1 (0.1) - -
Neoplasm 2 (0.1) 1 (0.1) 2 (0.1)
Nervous system disorders 3 (0.2) 2 (0.1) 2 (0.1)
Renal and urinary disorders - - 1 (0.1)
Reproductive system and breast disorders - 1 (0.1) -
Respiratory, thoracic, and mediastinal disorders 1 (0.1) - -
Skin and subcutaneous tissue disorders 1 (0.1) 1 (0.1) -
Surgical and medical procedures 1 (0.1) 1 (0.1) 1 (0.1)
Vascular disorders - - 2 (0.1)
*Listed if >1% in at least one cohort. Values within brackets indicate the number of patients with missing data for that variable. Data represent the numbers of
patients, with percentages within parentheses.
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not this strategy would decrease the rate of major cardi-
ovascular events should be tested in a long-term, rando-
mized clinical trial.
Although a limitation of this report is that it is based
on pooled data from 2 separate studies, both were per-
formed almost simultaneously with the same protocol in
two Mediterranean countries with similar lifestyle habits.
Thus, their results may be regarded as if they came from
a single, multinational study. Nonrandomized studies,
like this, provide a lower level of evidence than rando-
mized ones. But it in turn they do offer the advantage of
reflecting the actual effectiveness of treatments, given
that nonrandomization bias prescription occurs in clini-
cal practice. Other strengths include the naturalistic
dosing and the use of a spectrum of SUs in contrast to
previous clinical trials of TZDs. In general, patients in
the Pio + Met cohort presented a poorer clinical condi-
tion, so it is possible that biases related to the regres-
sion-to-the-mean phenomenon occur. It is also posible
that other unobserved variables may have accounted for
the differences among groups. As this is not a clinical
outcome study, it does not contribute answers to the
issue of cardiovascular prevention in patients with T2D
treated with TZDs. Also, among the cardiovascular risk
factors that the TZDs have the potential to improve
(other than dyslipoproteinemias), such as endothelial
dysfunction, inflammation, fibrinolysis, or arterial hyper-
tension, only the latter was examined in this study.
Finally, although the occurrence of fractures in this
study was incidental, there is an association established
between treatment with Pio and an increased risk of
bone fractures in the long term. Whether new fractures
would have been reported in these patients should they
have been followed for a longer time period is unknown.
Conclusions
Beyond a beneficial effect in glycemic control in patients
with T2D, Pio combinations evaluated in this study also
improved various metabolic variables associated with
cardiovascular risk. Importantly, Pio therapies were
associated with potentially greater antiatherogenic pro-
tection than SU + Met. While demonstration of actual
macrovascular risk reduction requires a long-term
assessment, the findings from this study in real clinical
settings support the use of these Pio combinations for
T2D second-line therapy, particularly in patients with
dyslipidemia.
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